Healthcare entity
Every one of those 1 sits in a single category, market-trends. Intraocular Lenses is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window.
Last mentioned: Mar 21, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Intraocular Lenses is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window. The 5 average consequence score is below the beat benchmark of 5.9 in the same window. We currently track 1 Healthcare story that mention Volume-Based Procurement, all published on March 21, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Volume-Based Procurement. Shared-story counts are live from our verified record — not editorial picks.
Shanghai Haohai Biological Technology Co., Ltd. has reported a retreat in its full-year net income, reflecting the intensifying impact of China's centralized procurement policies. The decline underscores the challenges facing domestic medtech leaders as they navigate margin compression in ophthalmology and heightened competition in the medical aesthetics market.
Source: Rttnews · rttnews.com
Volume-Based Procurement is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
